Previous research has shown that high expression of HAVCR2, IL-10, and VEGFR2 reprogrammed TAMs and induced hepatocellular carcinoma (HCC), mouse breast cancer, and triple-negative breast cancer (TNBC) immunosuppression (46–48); targeting TAMs with an anti-CSF1R antibody improved T-cell checkpoint immunotherapy in pancreatic cancer models (49, 50). This evidence concerns the gene CSF1R and pancreatic neoplasm.